Samuel A. Frank, MD
Samuel A. Frank, MD (Activity Chair)
Director, Huntington’s Disease Society of America Center of Excellence
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, MA

Contracted Research: Teva

Edward Wild, MB, BChir, PhD, MRCP
Edward Wild, MB, BChir, PhD, MRCP
MRC Clinician Scientist
UCL Institute of Neurology
Honorary Consultant Neurologist
National Hospital for Neurology & Neurosurgery
Queen Square, London

Consulting Fee (paid to employer): Ionis Pharmaceuticals; Roche Pharmaceuticals; Shire Pharmaceuticals

Ralf Reilmann, MD
Ralf Reilmann, MD
Founding Director
Muenster, Germany

Consulting Fee: AOP Orphan, Cure Huntington’s Disease Initiative Foundation, Desitin, Ipsen, ISIS Pharma, Link Medicine, Lundbeck, MEDA Pharma, Medivation, Neurosearch Inc., Omeros, Novartis, Pfizer, Prana Biotechnology, Raptor, Siena Biotech, Temmler Pharma, Teva, Uniqure, Vaccinex, Wyeth

Contracted Research: AOP Orphan, Bundesministerium für Bildung und Forschung (BMBF), Cure Huntington’s Disease Initiative Foundation, Desitin, Deutsche Forschungsgemeinschaft (DFG), Deutsches Zentrum für Neurodegeneration und Entzündung (DZNE), European Huntington’s Disease Network (EHDN), European Union (EU-FP7 program), High-Q-Foundation, Ipsen, ISIS Pharma, Link Medicine, Lundbeck, MEDA Pharma, Medivation, Neurosearch Inc., Omeros, Novartis, Pfizer, Prana Biotechnology, Raptor, Siena Biotech, Temmler Pharma, Teva, Uniqure, Vaccinex, Wyeth

Speakers Bureau: AOP Orphan, Cure Huntington’s Disease Initiative Foundation, Desitin, Ipsen, ISIS Pharma, Link Medicine, Lundbeck, MEDA Pharma, Medivation, Neurosearch Inc., Omeros, Novartis, Pfizer, Prana Biotechnology, Raptor, Siena Biotech, Temmler Pharma, Teva, Uniqure, Vaccinex, Wyeth

Executive Committee: Huntington Study Group


Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP 
Clinical Instructor in Medicine, Thomas Jefferson University Hospital 
Physician, Thomas Jefferson University Hospital 
University of Pennsylvania Health System 
Philadelphia, PA

No relevant financial relationships to disclose.


Vindico Medical Education staff report the following relationship(s):

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accredited By

Activity Details

Credit Type: AMA PRA Category 1 Credit
Credit Amount: 0.75 credit hour
Release Date: July 15, 2016
Expiration Date: July 15, 2017
Estimated Time to Complete Activity: 45 minutes
Registration Required: No
Fee for Activity: There is no fee for this educational activity.

Activity Description

Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system (CNS) characterized by abnormal involuntary movements, behavioral disturbance, cognitive dysfunction, and psychiatric disease. Currently, there is no established treatment to delay the onset or prevent the progression of HD, and available pharmacologic interventions for controlling the motor and non-motor aspects of the disease are limited. However, recent therapeutic advances, particularly in suppressing chorea, have been shown to have a favorable effect on motor function, safety, and quality of life. In this roundtable discussion, recorded immediately after the 2016 International Congress of Parkinson's Disease and Movement Disorders Meeting in Berlin, Germany, leading experts in HD explore some of the most recent evidence and latest developments in the treatment for this devastating disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the latest data of the use of predictive testing and biomarkers in patients who are carriers of the mutant Htt gene variant prior to conversion to manifest HD.
  • Evaluate the latest clinical data regarding the mechanism of action, efficacy, and safety of available and emerging agents for the management of chorea and other symptoms associated with HD.
  • Assess the utilization of emerging agents in the management of patients with HD.

Target Audience

The intended audience for the activity is neurologists, psychiatrists, and other health care professionals involved in the treatment of patients with HD.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the posttest and evaluation form. A score of at least 66% is required on the posttest in order to receive a certificate. There are no prerequisites, and there is no fee to participate in this activity or to receive CME credit. Credit is awarded upon successful completion of the posttest and evaluation form.



Conflict of Interest Policy / Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation Statement

This continuing medical education activity is provided by Vindico Medical Education.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Follow these steps to earn CME credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

Statement of Commercial Support

This activity is supported by an educational grant from Teva Pharmaceuticals.

Disclaimer Statement/ Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

The opinions expressed herein are those of the authors and do not necessarily represent the views of Vindico Medical Education. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact Vindico Medical Education at


Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Hardware / Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.